RIGImmune Logo.jpg
RIGImmune Announces Multiple Oral Presentations for Intranasal RIG-101 at European Respiratory Society Congress 2024
September 09, 2024 07:55 ET | RIGImmune
Pre-clinical studies for intranasal RIG-101, a first in class RIG-I agonist, demonstrate potent local innate immune stimulation and pan-viral activity against human rhinovirus, influenza and RSV...
Ancilia_Wordmark_Decorative_no R.png
Ancilia Biosciences Announces Closing of $4.2 Million Financing
July 17, 2024 07:00 ET | Ancilia Biosciences
Ancilia raised $4.2M to leverage CRISPR’s natural function to create bacterial therapies with immunity against the viruses that limit their effectiveness.
cmi_logo.png
[Latest] Global Crop Protection Chemicals Market Size/Share Worth USD 98.5 Billion by 2032 at a 4.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
February 13, 2024 11:30 ET | Custom Market Insights
Austin, TX, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Crop Protection Chemicals Market Size, Trends and Insights By Type (Herbicides,...
PDS Biotech Logo.png
PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™
February 16, 2023 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses
February 08, 2023 16:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
RIGImmune Logo.jpg
RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments
December 07, 2022 08:00 ET | RIGImmune
Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and pan-viral respiratory therapies Company also...
New Logo.png
Provectus Biopharmaceuticals Provides Update on Research into PV-10® Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
January 27, 2022 08:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene...
logo.gif
Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica
November 20, 2020 09:10 ET | Auris Medical AG
Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Moleaer 2020 Logo-01.jpg
Moleaer & ASU confirm nanobubbles produce reactive oxygen species, hydroxyl radicals, known to eliminate hard-to-kill pathogens
October 26, 2020 12:00 ET | Moleaer Inc.
Carson, CA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Moleaer, a leading nanobubble technology company, in collaboration with Arizona State University’s (ASU) Research Center for Nanotechnology Enabled...
Conduent_Registermark_Horizontal-black (002).png
Coronavirus (COVID-19) Tracking Now Integrated into Conduent Maven® Platform  
March 05, 2020 03:30 ET | Conduent Business Services, LLC
Maven’s COVID-19 tracking software module makes required reporting by state and local health authorities more efficient and cost-effective Company will demonstrate Maven’s capabilities at HIMSS...